The FDA label tells you one story about Zepbound side effects. A University of Pennsylvania team, analyzing more than 400,000 Reddit posts from 67,000 users over five years, tells another. Nearly half of real-world users reported at least one side effect, and roughly 13% described anxiety, depression, or insomnia that the clinical trials never cataloged (Penn Medicine, 2026). Menstrual changes showed up in about 4% of reports. This article puts both stories on the same page.
Three things make it different from the other tabs you have open:
- Dose-by-dose rates for nausea, vomiting, and diarrhea at 2.5, 5, 10, and 15 mg, pulled from the FDA label (2024)
- The side effects no one covers: Ozempic face, muscle loss, and the SURMOUNT-4 rebound data
- The safety gap between branded Zepbound and compounded tirzepatide, which now drives the single largest real-world adverse event signal
If you arrived here with a history of trauma, an eating disorder, or a body you have learned to monitor closely, this article flags where Zepbound intersects that. No moralizing, no minimization. Every percentage below is cited inline, and every action item is specific enough to take into your next appointment.
The Common Side Effects by Dose: What to Expect at 2.5, 5, 10, and 15 mg
Nausea does not climb with dose the way most people assume. It sits at 25% at 5 mg, rises to 29% at 10 mg, then drops back to 28% at 15 mg (FDA label, 2024). Vomiting and diarrhea do climb steadily. Vomiting runs 8%, 11%, 13% across the three maintenance doses. Diarrhea runs 19%, 21%, 23%.
Constipation actually falls as dose rises, from 17% at 5 mg to 11% at 15 mg. Two things explain this. Higher doses affect intestinal motility differently than lower ones, and by 15 mg most patients have been titrating for months, so the gut has adapted.
Severe GI events track dose more predictably: 1.7% at 5 mg, 2.5% at 10 mg, 3.1% at 15 mg (FDA label, 2024). Treatment discontinuation from GI side effects stays remarkably flat at 4.3%, 3.3%, and 4.3%. Translation: more than 95% of patients keep going, even when side effects are real.
| Dose | Nausea | Vomiting | Diarrhea |
|---|---|---|---|
| 5 mg | 25% | 8% | 19% |
| 10 mg | 29% | 11% | 21% |
| 15 mg | 28% | 13% | 23% |
One clarification that gets missed. The 2.5 mg starting dose is not therapeutic. It is a tolerance dose, designed to let your GI tract adapt before the drug reaches weight-loss range (FDA label, 2024). If you are on 2.5 mg and frustrated the scale is not moving, that is biology, not failure.
The UPenn Reddit study surfaced side effects barely mentioned in the label: fatigue, acid reflux, abdominal pain, and dizziness each appeared in more than 5% of real-world reports. Those do not mean you have a bad reaction. They mean the table you were reading was incomplete.
Your First 30 Days on Zepbound: A Week by Week Timeline
Week 1 (2.5 mg): GI symptoms often start within hours of your first injection and peak at 24 to 72 hours. Per FDA trial data, the average nausea episode lasts 3 to 4 days, diarrhea about 3 days, and vomiting 1 to 2 days. One Drugs.com reviewer described a rock settling in their stomach by evening, then dry heaving in their sleep and waking up sicker than their first trimester of pregnancy. That is the severe end, but it is not rare.
Week 2 (still 2.5 mg): Symptoms ease. Many patients notice the first signs of what the community calls food noise quieting. Penn Medicine researchers describe this as suppression of brain reward-center signaling around food preoccupation (Penn Medicine, 2025).
Weeks 3 to 4: Appetite suppression becomes more obvious. Early scale movement, often two to five pounds, is mostly water weight at this stage. Energy can dip as calorie intake drops sharply. Low-effort strategies help: protein at every meal, electrolytes once a day, and a 20-minute walk after dinner to offset fatigue.
Month 2 (dose increase to 5 mg): A new wave of GI symptoms typically arrives within 2 to 7 days of the first 5 mg injection. One patient described three days of hard vomiting followed by two more days of nausea after stepping up from 2.5 mg. This is expected, not a failure of the medication or of you.
Month 3 (stable or escalating to 7.5 mg): Symptom frequency roughly halves at a stable dose. Weight loss feels more consistent. Hair shedding often begins here, which section 7 covers in detail.
If a dose increase is intolerable, the FDA label explicitly allows you to delay escalation for 4 or more weeks. Script it for your provider: “I am not fully adapted to my current dose. Can we stay here another month before stepping up?” That conversation is built into the protocol.
Serious Side Effects You Need to Recognize Right Away
The list of serious adverse events is short and mostly rare. Rare does not mean hypothetical. The symptoms below move the conversation from wait and see to call today or ER now.
Thyroid C-cell tumors (boxed warning). Tirzepatide caused C-cell tumors in rats at clinically relevant exposures. Whether it does the same in humans is unknown, and no confirmed human cases of medullary thyroid carcinoma have been tied to Zepbound as of 2024 (FDA label). Contraindicated if you or a family member have MTC or MEN 2. Watch for a new neck lump, hoarseness, or trouble swallowing.
Pancreatitis. In the trials, 0.2% of Zepbound patients had adjudicated acute pancreatitis, the same rate as placebo (FDA label, 2024). Patients with prior pancreatitis were excluded from the studies, so their real risk is not quantified. Severe abdominal pain that radiates to your back, paired with persistent vomiting, is an ER trigger.
Gallbladder disease. Cholelithiasis ran 1.1% vs 1.0% placebo. Cholecystitis was more skewed, 0.7% vs 0.2%. Rapid weight loss itself precipitates gallstones. Right upper quadrant pain, fever, or yellowing skin warrants same-day care.
Kidney injury. The mechanism is dehydration from GI losses. Dr. Mary Claire Haver notes GLP-1s also reduce thirst signals, which compounds the risk in menopausal women already prone to lower hydration. Reduced urination or new confusion should not wait.
Allergic reactions. Hypersensitivity ran 5% vs 3% placebo (FDA label, 2024). Anaphylaxis is rare but reported.
Hypoglycemia. Only a clinical concern if you are on insulin or a sulfonylurea, where combined use pushes risk to 10.3%. For non-diabetic weight-loss patients, low blood sugar is not meaningful.
Triage checklist:
- Call your provider today: persistent vomiting that prevents hydration, right upper quadrant pain, new neck lump, mood shift that feels unsafe, vision change
- Go to the ER now: severe abdominal pain radiating to the back, anaphylaxis (swelling, difficulty breathing), sudden painless vision loss, signs of severe dehydration (confusion, no urine for 12+ hours)
Ozempic Face, Muscle Loss, and Rebound Weight: The Side Effects Nobody Talks About
None of the three are side effects of the drug in the narrow sense. They are side effects of losing 20% of your body weight quickly, which Zepbound happens to enable. Ignoring them is not the answer. The answer is a different framework.
Ozempic face. A 2025 AAO-HNSF study measured roughly 7% midface volume loss for every 10 kg lost on GLP-1 medications. Because Zepbound produces 20% to 22% body weight loss at 15 mg in SURMOUNT-1, facial volume loss risk is meaningfully higher than with Wegovy. Dr. Vinni Makin of the Cleveland Clinic describes it as “gauntness, sunken cheeks, new wrinkles and loose skin,” and makes the clinical point: it does not resolve on its own. Prevention means slower weight loss (1 to 2 pounds per week), adequate protein, and consistent sunscreen. Our tirzepatide vs semaglutide breakdown covers the facial volume math in detail.
Muscle and lean mass loss. About 25% to 30% of weight lost on Zepbound comes from lean tissue, consistent with any significant weight-loss method (SURMOUNT-1 body composition data). There is no direct myotoxic mechanism.
What preserves lean mass: 1.2 to 1.6 grams of protein per kg of body weight daily, resistance training at least twice a week, and keeping weight loss in the 1 to 2 pounds per week range. Dr. Mary Claire Haver recommends the higher end, 1.5 to 1.8 g/kg, for menopausal women. For more on that intersection, see hormonal belly fat. Creatine monohydrate at 3 to 5 g per day also has evidence for lean mass preservation during caloric restriction.
Rebound weight after stopping. SURMOUNT-4 followed 308 participants after 36 weeks of tirzepatide who were switched to placebo for 52 weeks. Within a year, 82.5% had regained at least 25% of their lost weight, and 24% had regained 75% or more. Cardiometabolic benefits reversed proportionally: with 75%+ regain, systolic blood pressure rose 10.4 mmHg, HbA1c rose 0.35%, and insulin resistance climbed 27% (SURMOUNT-4).
Read that the way the researchers meant it. This is not personal failure. It is what chronic disease biology does when treatment is withdrawn. The drug is a treatment, not a cure, in the same category as a blood pressure medication. If you are weighing whether to start Zepbound, you are weighing long-term therapy, and that is a legitimate question to bring to your provider.
Vision, Surgery, Birth Control, and Pregnancy: What the FDA Notes Actually Mean
Four items the label mentions in passing, each requiring a specific action if they apply to you.
Vision
A JAMA Ophthalmology pharmacovigilance review found NAION (“stroke of the optic nerve”) in 0.04% of GLP-1 users vs 0.02% of controls. Double the relative risk, but small in absolute terms, and irreversible once it happens. Dr. Howard Krauss recommends baseline and annual eye exams for anyone starting a GLP-1, and does not recommend stopping the medication. A separate signal: in patients with pre-existing diabetic retinopathy, rapid glucose correction can transiently worsen the disease, though long-term data is conflicting. Sudden painless vision loss is a same-day ophthalmology call.
Surgery
The guidance has shifted. The original June 2023 American Society of Anesthesiologists rule was to stop weekly GLP-1 medications one week before elective surgery, citing aspiration risk from delayed gastric emptying. The October 2024 multi-society update reversed most of that. Most patients should now continue their GLP-1, with individualized risk assessment. A liquid pre-op diet is often recommended for higher-risk patients. Script for your team: “I am on Zepbound, current dose X mg, last injection on Y. What is your protocol?”
Birth Control
Tirzepatide’s delayed gastric emptying reduces oral contraceptive peak levels by 55% to 66% and delays absorption by about two hours (FDA label). Practical translation: if you rely on the pill, switch to a non-oral method or add a barrier method for 4 weeks after starting Zepbound and 4 weeks after each dose increase. Nexplanon, a hormonal IUD, and Depo-Provera are unaffected because they bypass the GI tract. The pill is not.
Pregnancy
Zepbound is contraindicated in pregnancy, with animal studies showing fetal growth reductions during organogenesis. If you find out you are pregnant on Zepbound, call your provider and the Eli Lilly Pregnancy Registry at 1-800-LillyRx (1-800-545-5979). Do not stop silently. The registry helps future patients understand outcomes from unplanned exposures, and your provider will guide the transition.
Hair Loss, Mental Health, and the Trauma Informed Lens
Three topics the big sites skim. Each deserves more than a bullet.
Hair loss. This is telogen effluvium, not a direct drug effect. Rapid weight loss pushes up to 70% of scalp hairs from the growth (anagen) phase into the resting (telogen) phase prematurely. Onset is typically month 3, peak shedding hits months 4 to 6, and roughly 85% of cases fully restore by 12 months with adequate nutrition.
In the SURMOUNT trials, 7.1% of women experienced hair loss vs 0.5% of men, a 14-fold gap. Prevention: 1.2 to 1.6 g/kg protein daily, biotin 5,000 mcg, zinc 30 mg, vitamin D 1,000 to 2,000 IU with fat, and a ferritin check. If shedding persists past 6 months, ask about minoxidil. No permanent follicle damage occurs.
Mental health. In January 2024, the FDA concluded its investigation into GLP-1 medications and suicidal ideation. Its finding: no evidence of a causal link. The EMA reached the same conclusion in April 2024, and the FDA asked manufacturers to remove the warning from GLP-1 labels.
What the label still does not capture: roughly 13% of real-world GLP-1 users in the Penn Reddit analysis reported anxiety, depression, or insomnia. Dr. Sue Decotiis attributes many to mechanical causes like dehydration and low blood sugar, which are addressable. For the cortisol-sleep-mood menopause intersection, see cortisol and menopause. If you are in crisis, 988 is the call.
Trauma and disordered eating. Zepbound quiets food noise, and for many patients that is the most transformative part of treatment. Penn Medicine researchers also found the effect may be temporary, with food noise returning in some patients after about 5 months (Penn Medicine, 2025).
If you have a history of restrictive eating, orthorexia, or trauma that patterned your relationship to food, both the disappearance and the return of hunger cues can destabilize. This is not a reason to avoid Zepbound. It is a reason to screen before starting and work with a provider who will ask. For perimenopausal readers, the 4% menstrual irregularity signal from the Penn data adds another layer. Attribution is harder when hormones are already in flux, but the symptom is real.
Branded Zepbound vs Compounded Tirzepatide: Why the Side Effect Profile Can Differ
The single most reported adverse event for tirzepatide in the FDA’s FAERS database is not nausea. It is “incorrect dose administered,” with 19,461 reports and an 8-fold increase between 2022 and 2024 (PMC, 2025). The signal is driven largely by variable concentrations in compounded products.
The legal landscape shifted fast. During the 2023-2024 tirzepatide shortage, compounding pharmacies were legally permitted to produce tirzepatide. In October 2024, the FDA determined the shortage was resolved, and routine compounding is no longer legally permitted outside documented medical necessity.
In August 2024, more than 15,000 vials of compounded semaglutide and tirzepatide from one manufacturer were recalled for sterility issues. In September 2025, the FDA issued more than 50 warning letters to GLP-1 compounders. Dr. Spencer Nadolsky, an obesity medicine physician, put it this way: “There have been no studies assessing the safety or effectiveness of compounded versions of GLP-1 medications.”
What that means for your side effect profile:
- Dosing errors are the #1 real-world signal, and compounded products drive them
- Sterility is not guaranteed, which changes the calculus on injection site infections
- You may not know the actual concentration of what you are injecting, which makes titration harder
None of this is a reason to shame patients who used compounded tirzepatide during the shortage. That was legal, and for many people it was the only path to treatment. The relevant question is what you use going forward.
Compounded pharmacy safety checklist:
- Licensed 503A pharmacy or FDA-registered 503B outsourcing facility
- Certificate of Analysis confirming concentration, sterility, and contaminant testing
- Lot numbers and verifiable pharmacy address
- Any adverse event reported to FDA MedWatch at 1-800-FDA-1088
If you are evaluating telehealth providers for branded Zepbound or vetted tirzepatide access, our review of the best online tirzepatide options covers pharmacy credentialing, prescriber oversight, and what to ask before your first refill. Safe access is a clinical variable, not a marketing one.
Zepbound Side Effects FAQ
How long do Zepbound side effects last?
Most GI side effects are short-lived per episode. Trial data shows nausea lasting 3 to 4 days, diarrhea about 3 days, and vomiting 1 to 2 days. After 8 to 12 weeks at a stable dose, the overall frequency of GI symptoms drops by roughly half. Each dose escalation resets the clock, though later increases are usually milder than the first.
What should I expect from my first Zepbound dose?
Symptoms often start within hours of injection and peak between 24 and 72 hours. The 2.5 mg starting dose is a tolerance dose, not a therapeutic one, so the scale will not move yet. Keep meals small, avoid fatty and fried food for 48 hours, and hydrate. Call your provider if you cannot keep fluids down.
What happens when I increase my Zepbound dose?
Expect a 2 to 7 day wave of GI symptoms within a week of stepping up. One real-world report described three days of vomiting after moving from 2.5 mg to 5 mg. The FDA label explicitly allows you to stay at your current dose for 4 or more extra weeks if you are not ready. That is built into the protocol.
Are Zepbound side effects different for women, especially in menopause?
Yes in several directions. Women experience 7.1% hair loss vs 0.5% for men. GLP-1s reduce thirst signals, which raises dehydration risk in menopausal women already prone to low hydration. Combining Zepbound with hormone therapy produced 19.18% weight loss vs 13.96% alone in a 2025 cohort. See GLP-1 weight loss in menopause for the full picture.
What happens if I stop Zepbound?
SURMOUNT-4 showed 82.5% of people regained at least 25% of their lost weight within a year of stopping, and 24% regained 75% or more. Cardiometabolic benefits reversed proportionally, including blood pressure and insulin resistance. Obesity is a chronic disease. Stopping is a shared clinical decision with a maintenance plan, not a spontaneous move.
What should I tell my doctor about Zepbound side effects?
Bring specific scripts, not topics. Try “Can we delay my next dose increase by 4 weeks?” or “Can we check ferritin given the hair shedding?” Add “What is your surgical protocol for my current dose?” and “I need a non-oral birth control plan for the next 4 weeks.” Named requests get named answers.
Does Zepbound cause suicidal thoughts?
No established causal link. The FDA concluded in January 2024 that its investigation found no evidence GLP-1 medications cause suicidal thoughts or actions, and the EMA reached the same conclusion in April 2024. The FDA then requested removal of that warning from GLP-1 labels. If you are in crisis, call or text 988. You deserve support.
Looking for a tirzepatide provider? Our Tirzepatide hub covers dosing, microdosing, and side-effect mitigation. For the ranked provider list, see Best Tirzepatide Online.